Buprenorphine-naloxone therapy in pain management

Anesthesiology

Volumn 120, Issue 5, 2014, Pages 1262-1274

  Chen, Kelly Yan ^a   Chen, Lucy ^b   Mao, Jianren ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; METHADONE;

ANALGESIA; ANESTHESIA; CHRONIC PAIN; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HYPERALGESIA; MAINTENANCE THERAPY; NAUSEA; OPIATE ADDICTION; OUTPATIENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VOMITING;

AMBULATORY CARE; BUPRENORPHINE; CHRONIC PAIN; DRUG COMBINATIONS; HUMANS; NALOXONE; OPIOID-RELATED DISORDERS; PAIN MANAGEMENT; TREATMENT OUTCOME;

EID: 84899471309     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0000000000000170     Document Type: Review

References (72)

1. Toblin RL, Mack KA, Perveen G, Paulozzi LJ: A population-based survey of chronic pain and its treatment with prescription drugs. Pain 2011; 152:1249-55
2. Johannes CB, Le TK, Zhou X, Johnston JA, Dworkin RH: The prevalence of chronic pain in United States adults: Results of an Internet-based survey. J Pain 2010; 11:1230-9
3. Compton WM, Volkow ND: Major increases in opioid analgesic abuse in the United States: Concerns and strategies. Drug Alcohol Depend 2006; 81:103-7 (Pubitemid 41821793)
4. Paulozzi LJ, Budnitz DS, Xi Y: Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol Drug Saf 2006; 15:618-27 (Pubitemid 44404658)
5. Kroutil LA, Van Brunt DL, Herman-Stahl MA, Heller DC, Bray RM, Penne MA: Nonmedical use of prescription stimulants in the United States. Drug Alcohol Depend 2006; 84:135-43 (Pubitemid 44160579)
6. Okie S: A flood of opioids, a rising tide of deaths. N Engl J Med 2010; 363:1981-5
7. Campbell ND, Lovell AM: The history of the development of buprenorphine as an addiction therapeutic. Ann N Y Acad Sci 2012; 1248:124-39
8. Yokell MA, Zaller ND, Green TC, Rich JD: Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: An international review. Curr Drug Abuse Rev 2011; 4:28-41
9. Cowan A, Lewis JW, Macfarlane IR: Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmacol 1977; 60:537-45 (Pubitemid 8149539)
10. Tejwani GA, Rattan AK: The role of spinal opioid receptors in antinociceptive effects produced by intrathecal administration of hydromorphone and buprenorphine in the rat. Anesth Analg 2002; 94:1542-6 (Pubitemid 34556640)
11. Pfeiffer A, Brantl V, Herz A, Emrich HM: Psychotomimesis mediated by kappa opiate receptors. Science 1986; 233:774-6 (Pubitemid 16016229)
12. Jones HE: Practical considerations for the clinical use of buprenorphine. Sci Pract Perspect 2004; 2:4-20
13. Leander JD: Buprenorphine has potent kappa opioid receptor antagonist activity. Neuropharmacology 1987; 26:1445-7 (Pubitemid 17154903)
14. Chiang CN, Hawks RL: Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug Alcohol Depend 2003; 70(2 suppl):S39-47 (Pubitemid 36556059)
15. Brown SM, Holtzman M, Kim T, Kharasch ED: Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active. Anesthes iology 2011; 115:1251-60
16. Cone EJ, Gorodetzky CW, Yousefnejad D, Buchwald WF, Johnson RE: The metabolism and excretion of buprenorphine in humans. Drug Metab Dispos 1984; 12:577-81 (Pubitemid 14020828)
17. Jasinski DR, Pevnick JS, Griffith JD: Human pharmacology and abuse potential of the analgesic buprenorphine: A potential agent for treating narcotic addiction. Arch Gen Psychiatry 1978; 35:501-16 (Pubitemid 8337042)
18. Levine JD, Gordon NC, Fields HL: Naloxone dose dependently produces analgesia and hyperalgesia in postoperative pain. Nature 1979; 278:740-1 (Pubitemid 9160278)
19. Harris DS, Jones RT, Welm S, Upton RA, Lin E, Mendelson J: Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine. Drug Alcohol Depend 2000; 61:85-94
20. Strain EC, Moody DE, Stoller KB, Walsh SL, Bigelow GE: Relative bioavailability of different buprenorphine formulations under chronic dosing conditions. Drug Alcohol Depend 2004; 74:37-43 (Pubitemid 38457051)
21. Weinhold LL, Bigelow GE, Preston KL: Combination of naloxone with buprenorphine in humans. NIDA Res Monogr 1989; 95:485 (Pubitemid 20347313)
22. Simojoki K, Vorma H, Alho H: A retrospective evaluation of patients switched from buprenorphine (Subutex) to the buprenorphine/naloxone combination (Suboxone). Subst Abuse Treat Prev Policy 2008; 3:16
23. Alho H, Sinclair D, Vuori E, Holopainen A: Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend 2007; 88:75-8 (Pubitemid 46400304)
24. Daulouède JP, Caer Y, Galland P, Villeger P, Brunelle E, Bachellier J, Piquet JM, Harbonnier J, Leglise Y, Courty P: Preference for buprenorphine/naloxone and buprenorphine among patients receiving buprenorphine maintenance therapy in France: A prospective, multicenter study. J Subst Abuse Treat 2010; 38:83-9
25. Judd LL: Effective medical treatment of opiate addiction. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction. JAMA 1998; 280:1936-43
26. Mintzer IL, Eisenberg M, Terra M, MacVane C, Himmelstein DU, Woolhandler S: Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings. Ann Fam Med 2007; 5:146-50 (Pubitemid 46513484)
27. Schackman BR, Leff JA, Polsky D, Moore BA, Fiellin DA: Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care. J Gen Intern Med 2012; 27:669-76
28. Barry DT, Moore BA, Pantalon MV, Chawarski MC, Sullivan LE, O'Connor PG, Schottenfeld RS, Fiellin DA: Patient satisfaction with primary care office-based buprenorphine/naloxone treatment. J Gen Intern Med 2007; 22:242-5 (Pubitemid 47308818)
29. Fiellin DA, Moore BA, Sullivan LE, Becker WC, Pantalon MV, Chawarski MC, Barry DT, O'Connor PG, Schottenfeld RS: Long-term treatment with buprenorphine/naloxone in primary care: Results at 2-5 years. Am J Addict 2008; 17:116-20 (Pubitemid 351507728)
30. Parran TV, Adelman CA, Merkin B, Pagano ME, Defranco R, Ionescu RA, Mace AG: Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy. Drug Alcohol Depend 2010; 106:56-60
31. Collins GB, McAllister MS: Buprenorphine maintenance: A new treatment for opioid dependence. Cleve Clin J Med 2007; 74:514-20
32. Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, Collins J, Raisch D, Casadonte P, Goldsmith RJ, Ling W, Malkerneker U, McNicholas L, Renner J, Stine S, Tusel D; Buprenorphine/Naloxone Collaborative Study Group: Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 2003; 349:949-58 (Pubitemid 37064768)
33. Kamien JB, Branstetter SA, Amass L: Buprenorphine-naloxone versus methadone maintenance therapy: A randomised double-blind trial with opioid-dependent patients. Heroin Addict & Rel Clinical Problems 2008; 10:5-18
34. Raisch DW, Fye CL, Boardman KD, Sather MR: Opioid dependence treatment, including buprenorphine/naloxone. Ann Pharmacother 2002; 36:312-21 (Pubitemid 34126827)
35. Rapeli P, Fabritius C, Alho H, Salaspuro M, Wahlbeck K, Kalska H: Methadone vs. buprenorphine/naloxone during early opioid substitution treatment: A naturalistic comparison of cognitive performance relative to healthy controls. BMC Clin Pharmacol 2007; 7:5
36. Neumann AM, Blondell RD, Jaanimägi U, Giambrone AK, Homish GG, Lozano JR, Kowalik U, Azadfard M: A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction. J Addict Dis 2013; 32:68-78
37. Kreek MJ, LaForge KS, Butelman E: Pharmacotherapy of addictions. Nat Rev Drug Discov 2002; 1:710-26 (Pubitemid 37361544)
38. Rosenblum A, Marsch LA, Joseph H, Portenoy RK: Opioids and the treatment of chronic pain: Controversies, current status, and future directions. Exp Clin Psychopharmacol 2008; 16:405-16
39. Rosen K, Gutierrez A, Haller D, Potter JS: Sublingual buprenorphine for chronic pain: A survey of clinician prescribing practices. Clin J Pain 2013 [Epub ahead of print]
40. Mao J: Opioid-induced abnormal pain sensitivity: Implications in clinical opioid therapy. Pain 2002; 100:213-7 (Pubitemid 35449233)
41. Angst MS, Clark JD: Opioid-induced hyperalgesia: A qualitative systematic review. Anesthes iology 2006; 104:570-87
42. Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE: Clinical pharmacology of buprenorphine: Ceiling effects at high doses. Clin Pharmacol Ther 1994; 55:569-80 (Pubitemid 24192243)
43. Daitch J, Frey ME, Silver D, Mitnick C, Daitch D, Pergolizzi J Jr: Conversion of chronic pain patients from full-opioid agonists to sublingual buprenorphine. Pain Physician 2012; 15(3 suppl):ES59-66
44. Pade PA, Cardon KE, Hoffman RM, Geppert CM: Prescription opioid abuse, chronic pain, and primary care: A Co-occurring Disorders Clinic in the chronic disease model. J Subst Abuse Treat 2012; 43:446-50
45. Roux P, Sullivan MA, Cohen J, Fugon L, Jones JD, Vosburg SK, Cooper ZD, Manubay JM, Mogali S, Comer SD: Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: Reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone. Pain 2013; 154:1442-8
46. Kamei J, Saitoh A, Suzuki T, Misawa M, Nagase H, Kasuya Y: Buprenorphine exerts its antinociceptive activity via mu 1-opioid receptors. Life Sci 1995; 56:PL285-90
47. Koppert W, Ihmsen H, Körber N, Wehrfritz A, Sittl R, Schmelz M, Schüttler J: Different profiles of buprenorphine-induced analgesia and antihyperalgesia in a human pain model. Pain 2005; 118:15-22 (Pubitemid 41566581)
48. Lutfy K, Eitan S, Bryant CD, Yang YC, Saliminejad N, Walwyn W, Kieffer BL, Takeshima H, Carroll FI, Maidment NT, Evans CJ: Buprenorphine-induced antinociception is mediated by muopioid receptors and compromised by concomitant activation of opioid receptor-like receptors. J Neurosci 2003; 23:10331-7 (Pubitemid 37444610)
49. Gardell LR, Wang R, Burgess SE, Ossipov MH, Vanderah TW, Malan TP Jr, Lai J, Porreca F: Sustained morphine exposure induces a spinal dynorphin-dependent enhancement of excitatory transmitter release from primary afferent fibers. J Neurosci 2002; 22:6747-55 (Pubitemid 35386431)
50. Lee M, Silverman SM, Hansen H, Patel VB, Manchikanti L: A comprehensive review of opioid-induced hyperalgesia. Pain Physician 2011; 14:145-61
51. Steiner DJ, Sitar S, Wen W, Sawyerr G, Munera C, Ripa SR, Landau C: Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naïve patients with moderate to severe chronic low back pain: An enriched, randomized, double-blind, placebo-controlled study. J Pain Symptom Manage 2011; 42:903-17
52. Mitra F, Chowdhury S, Shelley M, Williams G: A feasibility study of transdermal buprenorphine versus transdermal fentanyl in the long-term management of persistent non-cancer pain. Pain Med 2013; 14:75-83
53. Yarlas A, Miller K, Wen W, Dain B, Lynch SY, Pergolizzi JV, Raffa RB, Ripa SR: A randomized, placebo-controlled study of the impact of the 7-day buprenorphine transdermal system on health-related quality of life in opioid-naïve patients with moderate-to-severe chronic low back pain. J Pain 2013; 14:14-23
54. Breivika H, Ljosaaa TM, Stengaard-Pedersenb K, Perssonc J, Arod H, Villumsene J, Tvinnemose D: A 6-months, randomised, placebo-controlled evaluation of efficacy and tolerability of a low-dose 7-day buprenorphine transdermal patch in osteoarthritis patients naïve to potent opioids. Scandinavian J Pain 2010; 1:122-41
55. Mercadante S, Porzio G, Ferrera P, Aielli F, Verna L, Tirelli W, Villari P, Casuccio A: Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: A 4-week, nonrandomized, open-label, uncontrolled observational study. Clin Ther 2009; 31:2134-8
56. Sittl R, Griessinger N, Likar R: Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: A multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther 2003; 25:150-68 (Pubitemid 36206743)
57. Böhme K: Buprenorphine in a transdermal therapeutic system-A new option. Clin Rheumatol 2002; 21(suppl 1):S13-6 (Pubitemid 34248143)
58. Griessinger N, Sittl R, Likar R: Transdermal buprenorphine in clinical practice-A post-marketing surveillance study in 13,179 patients. Curr Med Res Opin 2005; 21:1147-56 (Pubitemid 41140716)
59. Malinoff HL, Barkin RL, Wilson G: Sublingual buprenorphine is effective in the treatment of chronic pain syndrome. Am J Ther 2005; 12:379-84 (Pubitemid 41445134)
60. Berland DW, Malinoff HL, Weiner MA, Przybylski R: When opioids fail in chronic pain management: The role for buprenorphine and hospitalization. Am J Ther 2013; 20:316-21
61. Ferrari A, Coccia CP, Bertolini A, Sternieri E: Methadone-Metabolism, pharmacokinetics and interactions. Pharmacol Res 2004; 50:551-9
62. Chhabra S, Bull J: Methadone. Am J Hosp Palliat Care 2008; 25:146-50
63. Sotgiu ML, Valente M, Storchi R, Caramenti G, Biella GE: Cooperative N-methyl-D-aspartate (NMDA) receptor antagonism and mu-opioid receptor agonism mediate the methadone inhibition of the spinal neuron pain-related hyperactivity in a rat model of neuropathic pain. Pharmacol Res 2009; 60:284-90
64. Davis MP, Walsh D: Methadone for relief of cancer pain: A review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. Support Care Cancer 2001; 9:73-83 (Pubitemid 32246453)
65. Ripamonti C, Zecca E, Bruera E: An update on the clinical use of methadone for cancer pain. Pain 1997; 70:109-15 (Pubitemid 27179621)
66. Inturrisi CE, Colburn WA, Kaiko RF, Houde RW, Foley KM: Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. Clin Pharmacol Ther 1987; 41:392-401 (Pubitemid 17058923)
67. Caplehorn JR, Drummer OH: Fatal methadone toxicity: Signs and circumstances, and the role of benzodiazepines. Aust N Z J Public Health 2002; 26:358-62; discussion 362-3
68. Boyer EW, McCance-Katz EF, Marcus S: Methadone and buprenorphine toxicity in children. Am J Addict 2010; 19:89-95
69. Davis MP: Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain. J Support Oncol 2012; 10:209-19
70. Darke S, Duflou J, Torok M: The comparative toxicology and major organ pathology of fatal methadone and heroin toxicity cases. Drug Alcohol Depend 2010; 106:1-6
71. Bryson EO, Lipson S, Gevirtz C: Anesthesia for patients on buprenorphine. Anesthesiol Clin 2010; 28:611-7
72. Roberts DM, Meyer-Witting M: High-dose buprenorphine: Perioperative precautions and management strategies. Anaesth Intensive Care 2005; 33:17-25 (Pubitemid 40287592)